<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141331</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">CAPS treatment</dc:title>
<dc:description xml:lang="en">Non-steroidal anti-inflammatories, corticoids and antihistamines, as well as a great many other molecules, have classically been used to control the symptoms of cryopyrin-associated periodic syndromes (CAPS), with very few encouraging results. Knowledge of its genetic character, and its aetiopathogenesis associated with inflammasome and the production of interlekin-1 (IL-1) has led to the development of new therapeutic weapons that have not just obtained improvements of the symptoms and quality of life of the patients, but also managed to control the underlying inflammation. Results show that anakinra, an IL-1 receptor antagonist molecule, improved the clinical symptoms and the inflammatory markers of patients with CAPS has motivated research with other molecules directed against IL-1: rilonacept and canakinumab. It is likely that the use of these molecules could prevent the development of the late complications associated with chronic inflammation (AU)</dc:description>
<dc:creator>Ramos Polo, Eduardo</dc:creator>
<dc:creator>Jiménez Treviño, Santiago</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En el tratamiento de los síndromes periódicos asociados a la criopirina (CAPS), clásicamente se han usado los antiinflamatorios no esteroideos, glucocorticoides y antihistamínicos, además de un sinfín de otras moléculas, con resultados poco alentadores. El conocimiento de su carácter genético y de su etiopatogenia relacionada con el inflamasoma y la producción de interleucina 1(IL1) ha permitido el desarrollo de nuevas terapias biológicas que consiguen no sólo mejorar la sintomatología y la calidad de vida de los pacientes, sino que logran el control de la inflamación subyacente. Las terapias anti_IL-1 han demostrado en los pacientes con CAPS tener una respuesta clínica espectacular, con normalización de los marcadores inflamatorios. Es posible que el uso de estas moléculas evite el desarrollo de complicaciones tardías derivadas de la inflamación crónica (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);136(supl.1): 29-33, ene. 2011.</dc:source>
<dc:identifier>ibc-141331</dc:identifier>
<dc:title xml:lang="es">Tratamiento de los síndromes periódicos asociados a la criopirina (CAPS)</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d906^s22073</dc:subject>
<dc:subject>^d29487^s22006</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d54035^s22006</dc:subject>
<dc:subject>^d6792^s22073</dc:subject>
<dc:subject>^d52277^s22038</dc:subject>
<dc:subject>^d52277^s22006</dc:subject>
<dc:subject>^d30555^s22006</dc:subject>
<dc:subject>^d52275^s22073</dc:subject>
<dc:subject>^d24852^s22083</dc:subject>
<dc:subject>^d19331^s22073</dc:subject>
<dc:subject>^d53556^s22057</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d53556^s22033</dc:subject>
<dc:subject>^d28634^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201101</dc:date>
</metadata>
</record>
</ibecs-document>
